trial · primary record
Tislelizumab
Non-small Cell Lung Cancer
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 418 |
| Primary completion | 2026-10-29 |
| Primary endpoint | Confirmed overall response rate (ORR) |
| Registry ID | NCT05635708 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:46.241Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05635708
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Tislelizumab · compound